A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
Trial ID or NCT#
NCT01677390
Status
NOT RECRUITING
Purpose
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.
Official Title
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- * Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression* Previously treated with at least 1 tyrosine kinase inhibitor (TKI)* Measurable disease* Eastern Cooperative Oncology Group performance status 0 or 1* Adequate lung and renal function
Exclusion Criteria:
- * Prior treatment with anti-CD70-directed therapy* Received more than one prior treatment with an mTOR inhibitor
Contact us to find out if this trial is right for you.
Contact
Cancer Clinical Trials Office
650-498-7061
View on ClinicalTrials.gov
